For the year ended December 31, 2010, revenues were $1,557,000, compared to $668,000 for the same period of 2009. The increase of approximately $889,000 was due primarily to the following factors: an increase of $903,000 in OraDisc™ licensing fees and an increase of $138,000 in Aphthasol® product sales as we did not sell any Aphthasol® finished product to our domestic distributor during 2009. These increases were partially offset by decreases in Zindaclin® royalty and licensing fees of $87,000 due to our divestiture of this product in June 2010.
Research and Development
Research and development expenses for the fourth quarter of 2010 were $309,000, including $32,000 in share-based compensation, compared to $244,000, including $34,000 in share-based compensation, for the fourth quarter of 2009. The increase of approximately $65,000 in research and development expenses was primarily due to higher costs of $50,000 associated with the development efforts for our Altrazeal® and OraDisc™ technologies.
For the year ended December 2010, research and development expenses were $1.26 million, including $136,000 in share-based compensation, compared to $2.25 million, including $320,000 in share-based compensation, for the same period in 2009. The decrease of approximately $992,000 in research and development expenses was due primarily to decreases in direct research costs of $73,000, scientific personnel costs of $561,000, clinical testing expenses for our wound care technologies of $163,000, and regulatory consulting of $195,000.
Selling, general and administrative
Selling, general and admini
|SOURCE ULURU Inc.|
Copyright©2010 PR Newswire.
All rights reserved